| Literature DB >> 28798688 |
Arjun Muralidharan1, Thomas S W Park1, John T Mackie2, Luiz G S Gimenez1, Andy Kuo1, Janet R Nicholson3, Laura Corradini3, Maree T Smith1,4.
Abstract
Chronic low back pain (LBP), the leading cause of disability globally, is notoriously difficult to treat. Most rodent models of LBP mimic lumbar radicular pain rather than mechanical LBP. Here, we describe establishment of a new rat model of mechanical LBP that is devoid of a neuropathic component. Groups of adult male Sprague Dawley rats were anesthetized and their lumbar L4/L5 and L5/L6 intervertebral disks (IVDs) were punctured (0.5 mm outer diameter, 2mm-deep) 5 (LPB-5X), or 10 (LBP-10X) times per disk. Sham-rats underwent similar surgery, but without disk puncture. Baseline noxious pressure hyperalgesia of lumbar axial deep tissues, mechanical allodynia in the hindpaws and gait were assessed prior to surgery and once-weekly until study completion on day 49. The model was also characterized using pharmacologic and histologic methods. Good animal health was maintained for ≥ 49 days post-surgery. For LBP- but not sham-rats, there was temporal development of noxious pressure hyperalgesia in lumbar axial deep tissues at days 14-49 post-surgery. Importantly, there were no between-group differences in von Frey paw withdrawal thresholds or gait parameters until study completion. On day 49, significant histologic changes were observed in the L4/L5 and L5/L6 IVDs for LBP-10X rats, but not sham-rats. In LBP-10X rats, single bolus doses of morphine produced dose-dependent relief of primary and secondary mechanical hyperalgesia in lumbar axial deep tissues at L4/L5 and L1, respectively. In conclusion, our new rat model has considerable potential for providing novel insight on the pathobiology of mechanical LBP and for analgesic efficacy assessment of novel compounds.Entities:
Keywords: IVD histology; algometry; gabapentin; gait; intervertebral disks (IVD); mechanical allodynia; mechanical low back pain (LBP); rat model of LBP
Year: 2017 PMID: 28798688 PMCID: PMC5529395 DOI: 10.3389/fphar.2017.00493
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Details of group sizes for all pain behavioral and gait analysis experiments.
| Cohorts | Number of animals in each group | Experiments performed¶ | |||
|---|---|---|---|---|---|
| Naïve | Sham | LBP-5X | LBP-10X | ||
| 1 | 2 | 3 | 4 | – | PAT only at L4/L5 |
| 2 | 3 | 3 | 6 | – | PAT only at L1 |
| 3 | 3 | 3 | 6 | – | PAT at both L1 & L4/L5 |
| 4 | – | 3 | 4 | 5 | PAT at both L1 & L4/L5 |
| 5 | – | 3 | – | 9 | PAT at both L1 & L4/L5 |
| 6 | 4 | 4 | – | 4 | Gait analysis using CatwalkTM and PAT at both L1 & L4/L5 |
Median IVD scores∗ for (x/y)† based on histological findings for L4/L5 and L5/L6 IVDs of LBP-10X and sham-rats.
| Sham ( | LBP-10X ( | |
|---|---|---|
| Loss of sharp boundary between NP and AF at cranial and caudal aspect of disk | 0/0 | 2/2 |
| Loss of sharp boundary between NP and AF at dorsal and ventral aspect of disk | 0/0 | 2/2 |
| Disruption of AF | 0/0 | 2/2 |
| Degeneration/disorganization of NP | 0/0 | 1/1 |
Dose-dependent extent and duration of anti-hyperalgesia [mean (±SEM) ΔPAT AUC values] evoked by single s.c. doses of morphine and single i.p. bolus doses of gabapentin, meloxicam and amitriptyline in LBP-10X rats.
| Test compound and route of administration∗ | Number of rats tested | Lumbar 1 | Lumbar 4/5 | ||
|---|---|---|---|---|---|
| Dose (mg/kg) | ΔPAT AUC | Dose (mg/kg) | ΔPAT AUC | ||
| Morphine (s.c.) | 6 | 0.1 | 159.3 (43.5) | 0.1 | 171.6 (44.8) |
| 6 | 0.3 | 477.5 (66.6)¶ | 0.3 | 461.9 (80.8)¶ | |
| 6 | 1 | 625.4 (87.7)¶ | 1 | 648.6 (85.5)¶ | |
| 14 | Vehicle | 15.8 (14.4) | Vehicle | 57.03 (13.8) | |
| Gabapentin (i.p.) | 6 | 30 | 177.8 (81.5) | 30 | 196 (90.5) |
| 6 | 60 | 128.1 (55.8) | 60 | 126.4 (49.9) | |
| 7 | 100 | 267.7 (66.1) | 100 | 273.6 (73.4) | |
| 14 | Vehicle | 62.4 (14.0) | Vehicle | 57.6 (13.8) | |
| Meloxicam (i.p.) | 6 | 3 | 92.93 (43.6) | 3 | 97.63 (48.0) |
| 6 | 10 | 188.7 (85.7) | 10 | 193.9 (84.3) | |
| 6 | 30 | 233.9 (99.7) | 30 | 264.6 (100.2) | |
| 14 | Vehicle | 65.35 (14.4) | Vehicle | 57.03 (13.8) | |
| Amitriptyline (i.p.) | 6 | 1 | 83.95 (25.7) | 1 | 98.49 (35.4) |
| 7 | 3 | 88.8 (44.4) | 3 | 72.43 (36.7) | |
| 6 | 7 | 62.66 (25.7) | 7 | 58.6 (26.3) | |
| 14 | Vehicle | 62.4 (14.0) | Vehicle | 57.6 (13.8) | |
Comparison of the novel rat models (LBP-5X and LBP-10X) of chronic mechanical LBP with previously reported rodent models of LBP.
| Significant pain nocifensive behaviors | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Gender/species | Model induction | Study duration | Body weight changes | Mechanical allodynia | Cold allodynia | Pressure hyperalgesia¶ | Thermal hyperalgesia | Gait changes | Reference |
| Male/SD | Annular puncture of L4/L5 and L5/L6 IVDs 5 times each using 25G needle (0.5 mm diameter, 2 mm deep) | 49 days | No | No | NA | Yes | NA | NA | – |
| Annular puncture of L4/L5 and L5/L6 IVDs 10 times each using 25G needle (0.5 mm diameter, 2 mm deep) | 49 days | No | No | NA | Yes | NA | No | – | |
| Male/SD | Application of CFA to the lumbar L4 spinal nerve | 14 days | No | Yes | NA | NA | Yes | NA | |
| Male/SD | Lumbar L5/L6 facet joint compression injury | 28 days | NR | Yes | NA | Yes | NA | NA | |
| Male and Female/ SD | Chronic compression of L5 DRG | 42 days | NR | NA | NA | NA | Yes | NA | |
| Female/SD | Posterior puncture of L4/L5 IVD using 0.4 mm diameter needle, and removal of nucleus pulposus by injecting small amount of air | 21 days | NR | NA | NA | NA | NA | NA | |
| Male/SD | Annular puncture of L4/L5 and L5/L6 IVDs using a microsurgical drill of either (i) 0.5 mm diameter; 2 mm deep or (ii) 0.8 mm diameter; 2 mm deep and removal of the nucleus pulposus | 49 days | NR | No | NA | Yes | NA | No | |
| Male/SD | Midline puncture of L3/L4, L4/L5, and L5/L6 IVDs using a 26 g needle (3 mm deep) and injection of 2.5 μL of PBS | 42 days | Minor reduction in LBP group | Yes | NA | NA | Yes | Yes | |
| Male/SD | Posterior or Anterior annular puncture of L4/L5 IVD (21 g needle, 3 mm deep) | 56 days | NR | Posterior: Yes Anterior: No | NA | NA | Posterior and Anterior: Yes; but minor | No | |
| Male/SD | Annular puncture of L3/L4, L4/L5 L5/L6 using 26G needle at either 1.5 mm (shallow) or 3 mm (deep) with injection of (i) PBS (ii) TNFα, (iii) NGF/VEGF | 42 days | No | Yes for both shallow and deep punctures | NA | NA | NA | NA | |
| Male/SPARC-null | Inactivation of SPARC IVD protein | 78 weeks | NR | No | Yes | NA | No | NA | |